A New Hormone-Suppressing Treatment for Advanced Prostate Cancer Increases Efficacy While Reducing Adverse Effects

Prostate cancer is one of the two most common cancers in men (the other is lung cancer). Unlike many other cancers, prostate cancer cells depend on male hormones called androgens to grow and multiply. Suppressing androgens is therefore a fundamental strategy in prostate cancer treatment... While local treatments such as surgery and radiotherapy are sufficient for early-stage prostate cancer, systemic treatments are needed in advanced disease. Today, many androgen-suppressing drugs and methods are used in advanced prostate cancer, and new drugs are added every year.
In advanced prostate cancer, drugs called LHRH agonists, given as injections every 3 months, are the first-choice medications for reducing testosterone levels. Their main disadvantages are an initial temporary increase in testosterone levels, which we call the flare effect, and a delay in hormone suppression. Relugolix is a new drug that differs from LHRH agonists (see the mechanism below). A GnRH receptor antagonist taken orally as a pill, relugolix, has been shown in earlier studies to produce a rapid decrease in testosterone levels. ASCO 2020 Virtual Congress was where Neal and colleagues presented the HERO study, which compared the efficacy and safety of relugolix with leoprolid acetate in advanced prostate cancer in a phase-III clinical trial.
The HERO study enrolled 934 patients, who were randomized in a 2:1 ratio to two arms:
- In the Relugolix arm, 624 patients received a daily oral pill of 120 mg (360 mg on the first day), and
- In the Leuprolid acetate arm, 310 patients received a 22.3 mg sc injection every 3 months.
The study's primary endpoint was to achieve castration at week 48 (testosterone level <50 ng/ml). Other endpoints were the speed of achieving castration, PSA response, FSH levels at week 24 and the speed at which testosterone levels returned to normal at the end of treatment.
According to the study results:
- At week 48, relugolix was found to be at least as effective as leuprolid acetate at suppressing testosterone: 96.7% in the relugolix arm and 86.8% in the leuprolid arm).
- Relugolix was also better than leuprolide acetate in all additional parameters examined: PSA response on day 15, the proportion of cases with testosterone <50 ng/ml on day 15, the proportion with testosterone <20 ng/ml on day 15, the proportion with testosterone <50 ng/ml on day 4 and FSH levels at week 24. All the defined targets were significantly better in favor of relugolix.
- Testosterone levels also returned to normal more rapidly in the relugolix group at the end of treatment.
- In terms of adverse effects, the rate of major cardiac events was 54% lower in the relugolix group.
What does this study mean for us?
In this study, relugolix provides faster and more effective castration (androgen suppression). Its important advantages are that it is the first GnRH receptor antagonist used orally as a pill, does not require hospital visits for injections, allows testosterone levels to rise faster and better after treatment is stopped, and has fewer cardiac adverse effects. However, questions remain about potential adherence problems because it is taken orally, the need for more frequent testosterone monitoring, whether it can be combined with other oral treatments and the cost of treatment.
In conclusion, relugolix appears to have the potential to become the new standard for testosterone suppression in prostate cancer treatment.
*
- Advanced prostate cancer treatment – its history and the current position
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.